Moleculin Biotech Depreciation & Amortization Growth & History (MBRX)

Moleculin Biotech's depreciation and amortization was $90,000 for fiscal 2025.

View full Moleculin Biotech company overview

Moleculin Biotech annual depreciation and amortization history

Moleculin Biotech annual depreciation and amortization

Fiscal yearPeriod endedDepreciation and amortizationChangeGrowth
20252025-12-31$90,000−$36,000−28.57%
20242024-12-31$126,000−$1,000−0.79%
20232023-12-31$127,000−$3,000−2.31%
20222022-12-31$130,000−$34,000−20.73%
20212021-12-31$164,000−$36,000−18.00%
20202020-12-31$200,000$1,000+0.50%
20192019-12-31$199,000$131,000+192.65%
20182018-12-31$68,000$50,000+277.78%
20172017-12-31$18,000$12,000+200.00%
20162016-12-31$6,000

Moleculin Biotech depreciation and amortization trends

Over the last five fiscal years, Moleculin Biotech's depreciation and amortization decreased from $200,000 to $90,000, a change of −$110,000. The latest reported quarter, Q2 2026, shows $8,000.

About the metric

What depreciation and amortization mean

Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.

Calculation and source

Reported depreciation and amortization

TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Moleculin Biotech source filings ↗

Community posts

It’s quiet here.

No posts about MBRX yet. Start the conversation.

Write the first post